AlliancePharma Closes Previously Announced Private Placement with Persistence Capital Partners

Pharmaceutical Investing

AlliancePharma has announced that it has issued an aggregate of 40 000 Series A Preferred Shares to Persistence Capital Partners. That is in connection with the $4,000,000 private placement, announced on July 4 of this year.

AlliancePharma Inc. (TSX VENTURE:APA) has announced that it has issued an aggregate of 40 000 Series A Preferred Shares to Persistence Capital Partners. That is in connection with the $4,000,000 private placement, announced on July 4 of this year.
According to the press release:

On September 28, 2016, the shareholders of the Corporation approved the creation of preferred shares of the Corporation issuable in series. Pursuant to the terms of the Private Placement, the Corporation issued 38,744 Series A Preferred Shares to Persistence Capital Partners II, L.P. (“PCP II”) and 1,256 Series A Preferred Shares to Persistence Capital Partners II (International), L.P. (collectively with PCP II, “PCP”) on October 20, 2016. PCP is a Montreal-based private equity fund that targets investment opportunities with strong growth potential in the healthcare sector.

Read the complete press release here.

private placement Company News